Video Experimental Relacionado

Updated: Sep 10, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Los beneficios y peligros de la adición de bevacizumab a la quimioterapia neoadyuvante para el cáncer de ovario

Zeyi Zhao¹, Lei Cheng², Xin Tong³

¹Department of Oncology, Jining NO.1 People's Hospital, Jining, China.

Future oncology (London, England)

|August 22, 2025

Resumen

La adición de bevacizumab a la quimioterapia neoadyuvante para el cáncer de ovario avanzado mejora las tasas óptimas de citorreducción pero aumenta el riesgo de perforación gastrointestinal. Se necesita más investigación para equilibrar la eficacia y la toxicidad en pacientes con cáncer de ovario.

Área de la Ciencia:

En el campo de la oncología
Oncología ginecológica
Farmacología clínica

Sus antecedentes:

El cáncer de ovario en estadio avanzado (AOC) presenta importantes desafíos de tratamiento.
La quimioterapia neoadyuvante (NACT) es un enfoque estándar para el AOC.
El bevacizumab, un agente antiangiogénico, se explora para mejorar la eficacia de NACT.

Objetivo del estudio:

Evaluar la eficacia y toxicidad de bevacizumab combinado con NACT en AOC.
Para comparar los resultados entre el bevacizumab-NACT y el estándar-NACT.

Principales métodos:

Revisión sistemática y metanálisis de ensayos clínicos aleatorizados, estudios de cohorte y series de casos.
Busqué en las bases de datos de PubMed, EMBASE, Scopus y Web of Science.
Incluidos los estudios publicados entre noviembre de 2010 y diciembre de 2024.

Principales resultados:

Bevacizumab-NACT aumentó significativamente la tasa de reducción óptima de las células (RR: 1,17, P=0,02).
No se observaron diferencias significativas en la citorreducción completa, la realización de la cirugía, las complicaciones de la herida, la trombogénesis o las infecciones.
Se observó un aumento del riesgo de perforación gastrointestinal en el grupo de bevacizumab-NACT (RR: 6,97, P=0,02).

Conclusiones:

La adición de bevacizumab a NACT mejora la viabilidad óptima de la citorreducción en AOC.
El tratamiento combinado se asocia con un mayor riesgo de perforación gastrointestinal.
La selección y el seguimiento cuidadosos de los pacientes son cruciales cuando se utiliza bevacizumab-NACT.

Palabras clave:

El tratamiento con bevacizumab la eficacia quimioterapia neoadyuvante Cáncer de ovario toxicidad

Más Videos Relacionados

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Videos de Conceptos Relacionados

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...